Neuronetics, Inc. announced that Aetna has updated its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with MDD (major depressive disorder). This expanded access follows the recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS as the first and only TMS treatment cleared as a first-line add-on for adolescents aged 15-21. The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications.

Aetna is one of the largest health plans in the country with over 19.4 million lives covered through its commercial policies nationwide. The TMS policy update is effective immediately. This policy update builds on recent momentum from both commercial and government payers to expand adolescent coverage for TMS Therapy.

Neuronetics previously announced updated policies through payers such as Medi-Cal and Humana. In addition to being the first and only TMS company with FDA clearance for adolescent treatment, Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.